medigraphic.com

2007, Number 3

<< Back Next >>

Arch Cardiol Mex 2007; 77 (3)

Paradigms and paradoxes of left ventricular hypertrophy: from the research laboratory to the clinical consultation

Escudero EM, Pinilla OA

Language: Spanish
References: 50
Page: 237-248
PDF size: 267.25 Kb.


ABSTRACT

Cardiac hypertrophy can occur as an adaptative response to increased cardiac workload. Different types of cardiac hypertrophy arise from a combination of genetic, physiologic, and environmental factors. When hypertophic growth of the heart leads to left ventricular dysfunction and heart failure, the response is considered as maladaptive or pathological hypertrophy. After analyzed left ventricular functional and structural changes in rats induced by arterial hypertension, banding of aortic root, isoproterenol administration, or myocardial infarction, as well as in patients with arterial hypertension, aortic stenosis, or hypertrophic miocardiopathy, we found a maladaptive response considered as pathological hypertrophy. However, the adaptation of the left ventricle, found in response to physical activity or to pregnancy in humans, seems to help the heart adapt to the increase in workload acting as physiological hypertrophy. These considerations allow us to speculate for the use of future interventions to stimulate the development of physiological hypertrophy in several pathological situations or to change a pathological into a physiological response.


REFERENCES

  1. Frey N, Olson EN: Cardiac hypertrophy: the good, the bad and the ugly. Annu Rev Physiol 2003; 65: 45-79.

  2. Russel B, Motlagh D, Ashley WW: Form follows function: How muscle shape is regulated by work. J Appl Physiol 2000; 88: 1127-1132.

  3. Sadoshima J, Izumo S: The cellular and molecular response of cardiac myocytes to mechanical stress. Annu Rev Physiol 1997; 59: 551-571

  4. Urbanek K, Quaini F, Tasca G, Torella D, Castaldo C, Nadal-Ginard B, et al: Intense myocyte formation from cardiac stem cells in human cardiac hypertrophy. Proc Natl Acad Sci USA 2003; 100(18): 10440–10445.

  5. Devereux RB, Savage DD, DRayer JIN, Laragh JH: Left ventricular hypertrophy and function in high-, normal-, and low-renin forms of essential hypertension. Hypertension 1982; 4: 524-531.

  6. Devereux RB, Lutas EM, Casale PN, Kligfield P, Eisenberg RR, Hammond IW, et al: Standarization of M-Mode echocardiographic left ventricular anatomic measurements. J Am Coll Cardiol 1984; 4: 1222-1230.

  7. Levy D, Anderson KM, Plehn J, Savage DD, Christiansen JC, Castelli WP: Echocardiographically determined left ventricular structural and functional correlates of complex or frequent ventricular arrhythmias on one-hour ambulatory electrocardiographic monitoring. Am J Cardiol. 1987; 59(8): 836-840.

  8. Levy D, Savage DD, Garrison RJ, Anderson KM, Kannel WB, Castelli WP: Echocardiographic criteria for left ventricular hypertrophy: The Framingham heart study. Am J Cardiol 1987; 59: 956-960.

  9. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH: Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114(5): 345-352.

  10. Ganau A, Devereux RB, Roman MJ, De Simone G, Pickering TG, Saba PS, et al: Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol 1992; 19: 1550-1558.

  11. Marcus R, Krause L, Weder AB, Dominguez-Meja A, Schork NJ, Julius S: Sex-specific determinants of increased left ventricular mass in the Tecumseh Blood Pressure Study. Circulation 1994; 90(2): 928-936.

  12. Liao Y, Cooper RS, McGee DL, Mensah GA, Ghali JK: The relative effects of left ventricular hypertrophy, coronary artery disease, and ventricular dysfunction on survival among black adults. JAMA 1995; 273: 1592-1597.

  13. Jarzembowski TM, Janicki PK, Sukernik MR: Presence of concentric left ventricular remodeling and concentric left ventricular hypertrophy are associated with increased intraoperative fluid administration during large bowel surgery. Anesthesiology 2005; 103: A446.

  14. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al: Chamber Quantification Writing Group; American Society of Echocardiography’s Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18(12): 1440-1463.

  15. Escudero EM, de Lena S, Cingolani HE: Estructura y función del ventrículo izquierdo en jóvenes estudiantes varones de la Universidad Nacional de La Plata con hipertensión arterial en estadio I. Medicina 1997; 57: 181-190.

  16. Escudero EM, De Lena S, Graff-Iversen S, Almiron M, Cingolani HE: Left ventricular diastolic function in young men with high normal blood pressure. Can J Cardiol 1996; 10: 959-964.

  17. Devereux RB, Reichek N: Echocardiographic determinations of left ventricular mass in man: anatomic validation of the method. Circulation 1977; 55: 613-618.

  18. Yamazaki T, Komuro I, Yazaki Y: Role of the rennin – angiotensin system in cardiac hypertrophy. Am J Cardiol 1999; 83: 53H-57H.

  19. Garciarena CD, Ennis IL, Escudero EM, Pérez NG, Cingolani HE: La regresión de la hipertrofia cardíaca inducida por inhibición del NHE-1 se acompaña de disminución de la expresión de calcineurina Ab. Medicina 2005; 65(Supl. II): 181-182.

  20. Ennis IL, Escudero EM, Pérez NG, Camilión de Hurtado MC, Cingolani HE: Regression of isoproterenol induced myocardial hypertrophy by Na+/H+ exchanger inhibition. Hypertension 2003; 41(6): 1324-1329.

  21. Aiello EA, Villa-Abrille MC, Escudero EM, Portiansky EL, Pérez NG, Camilión de Hurtado MC, et al: Myocardial hypertrophy of normotensive Wistar-Kyoto rats. Am J Physiol Heart Circ Physiol 2004; 286: H1229-H1235.

  22. Pérez NG, Escudero EM, Portianski EL, Camilión de Hurtado MC, Cingolani HE. Regression and prevention of hypertrophy and fibrosis by Na+/H+ exchange inhibition. J Mol Cell Cardiol 2002; 34: A 17.

  23. Pérez NG, Piaggio MR, Ennis IL, Garciarena CD, Morales C, Escudero M, et al: Phosphodiesterase 5A Inhibition induces Na+/H+ exchanger blockade and protection against myocardial Infarction. Hypertension. 2007; 49: 1095-1103.

  24. Cingolani HE, Rebolledo OR, Portiansky EL, Pérez NG, Camilión de Hurtado MC. Regression of hypertensive myocardial fibrosis by Na+/H+ exchange inhibition. Hypertension 2003; 41(2): 373-377.

  25. Escudero EM, Tufare AL, Rebolledo O, Pellegrini L, Lobrutto C: Serum carboxyl-terminal propeptide of procollagen type I in exercise-induced left ventricular hypertrophy. Clin Cardiol 2004; 27(8): 471-474.

  26. Kannel WB, Dauenberg AL, Levy D: Population implications of electrocardiographic left ventricular hypertrophy. Am. J Cardiol 1987; 60: 851-931.

  27. Levy D, Garrison RJ, Savage DD: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-1566.

  28. Levy D, Salomon M, D’Agostino RB, Belanger AJ, Kannel WB: Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation, 1994; 90: 1786-1793.

  29. Casale PN, Devereux RB, Milner M, Zulio G, Harshfield GA, Pickering TG, et al: Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Arch Intern Med 1986; 105: 173-178.

  30. Schillaci G, Verdecchia P, Porcellati C, Cuccurullo O, Cosco C, Perticone F: Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension 2000; 35: 580-586.

  31. Brown DW, Giles WH, Croft JB. Left ventricular hypertrophy as a predictor of Coronary Heart Disease Mortality and the effect of hypertension. Am Heart J 2000; 14: 848-856.

  32. East MA, Jollis JG, Nelson CL, Marks D, Peterson ED: The influence of left ventricular hypertrophy on survival in patients with coronary artery disease: Do race and gender matter? J Am Coll Cardiol 2003; 41: 949-954.

  33. Ghali JK, Liao Y, Cooper RS: Influence of left ventricular geometric patterns on prognosis in patients with or without coronary artery disease. J Am Coll Cardiol 1998; 31: 1635-1640.

  34. Palmon LC, Reichek N, Yeon SB, Clark NR, Brownson D, Hoffman E, et al: Intramural myocardial shortening in hypertensive left ventricular hypertrophy with normal pump function. Circulation 1994; 89(1): 122-31.

  35. Lutas EM, Devereux RB, Reis G, Alderman MH, Pickering TG, Borer JS, et al: Increased cardiac performance in mild essential hypertension: left ventricular mechanics. Hypertension 1985; 7: 979-988.

  36. Shimuzu G, Hirota Y, Kita Y, Kawamura K, Saito T, Gaasch WH: Left ventricular midwall mechanics in systemic arterial hypertension: myocardial function is depressed in pressure-overload hypertrophy. Circulation 1991; 83: 1676-1684.

  37. Devereux RB, Roman MJ, Palmieri V, Okin PM, Boman K, Gerdts E, et al: Left ventricular wall stresses and wall stress-mass-heart rate products in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE study. J Hypertension 2000; 18: 1129-1138.

  38. Aurigemma GP, Silver KH, Fox MA, Gaasch WH: Depressed midwall and long axis shortening in hypertensive left ventricular hypertrophy with normal ejection fraction. J Am Coll Cardiol 1995; 26: 195-202.

  39. Escudero EM, Tufare AL, Ennis IL, Garciarena CD, Pinilla OA, Carranza VB: Análisis ecocardiográfico del efecto de diferentes inhibidores del intercambiador Na+/H+ sobre la estructura y función sistólica del ventrículo izquierdo en ratas espontáneamente hipertensas. Medicina 2006; 66: 392-398.

  40. D’hooge J, Heimdal A, Jamal F, Kukulski T, Bijnens B, Rademakers F, et al: Regional strain and strain rate measurements by cardiac ultrasound: principles, implementation and limitations. Eur J Echocardiogr 2000; 1(3): 154-170.

  41. Tufare AL, Escuero EM, Ankudowicz V: Deterioro temprano de la contractilidad en la hipertrofia secundaria a hipertensión. Revista FAC 2005; 34 (Supl. II): 53.

  42. Pérez NG, Hashimoto K, McCune S, Altschuld RA, Marbán E: Origin of contractile dysfunction in heart failure: calcium cycling versus myofilaments. Circulation 1999; 99: 1077-1083.

  43. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, et al: A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998; 93: 215-228.

  44. Cingolani OH, Yang X-P, Cavasin MA, Carretero OA: Increased systolic performance with diastolic dysfunction in adult spontaneously hypertensive rats. Hypertension 2003; 41(2): 249-254.

  45. Vasan RS, Benjamin EJ, Levy D: Congestive heart failure with normal left ventricular systolic function. Clinical approaches to the diagnosis and treatment of diastolic heart failure. Arch Intern Med 1996; 156(2): 146-157.

  46. Mandinov L, Eberli FR, Seiler C, Hess OM: Diastolic Heart Failure. Cardiovasc Res 2000; 45(4): 813-825.

  47. Tufare AL, Escudero EM, Camilión de Hurtado MC: Hipertrofia ventricular izquierda y progresión a la insuficiencia cardíaca en ratas espontáneamente hipertensas. XI Congreso Argentino de Hipertensión Arterial. 6-9 de Mayo 2004, Buenos Aires, Argentina.

  48. Matsui H, MacLennan DH, Alpert NR, Periasamy M: Sarcoplasmic reticulum gene expression in pressure overload-induced cardiac hypertrophy in rabbit. Am J Physiol 1995; 268 (1 Pt 1): C252-258.

  49. Williams RS: Apoptosis and Heart Failure. N Engl J Med 1999; 341(10): 759-760.

  50. Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH, et al: Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 2006; 113(17): 2089-2096.




2020     |     www.medigraphic.com